研究疾病:
|
类风湿关节炎
|
研究疾病代码:
|
|
Target disease:
|
rheumatoid arthritis
|
Target disease code:
|
研究类型:
Study type:
|
干预性研究
Interventional study
|
研究设计:
Study design:
|
随机平行对照
randomized controlled trial(parallel group design)
|
研究所处阶段:
Study phase:
|
上市后药物
Post-marketing clinical trial
|
研究目的:
|
本研究采用祛风止痛胶囊治疗类风湿关节炎,评价其临床疗效和安全性,及对类风湿关节炎适应证候的临床疗效差异,为祛风止痛胶囊协同甲氨蝶呤治疗类风湿关节炎,提供循证医学证据。
|
Objectives of Study:
|
In this study, Qufengzhitong capsule was used to treat rheumatoid arthritis, and its clinical efficacy and safety were evaluated, as well as the difference of clinical efficacy in treating rheumatoid arthritis, which provided evidence-based medicine for Qufengzhitong capsule combined with methotrexate to treat rheumatoid arthritis.
|
药物成份或治疗方案详述:
|
|
Description for medicine or protocol of treatment in detail:
|
|
纳入标准:
|
1.符合2010年美国风湿病学会(ACR)/欧洲抗风湿联盟(EULAR)RA分类标准;
2.中医辨证为风(寒)湿痹阻证或肝肾不足证;
3.年龄18~75周岁,性别不限;
4.DAS28(CRP)评分>3.2;
5.入组前受试者口服糖皮质激素,必须在入组前至少4周内将剂量稳定至相当于≤10mg/日泼尼松的剂量,且入组后用药剂量保持不变;
6.入组前使用传统改善病情抗风湿药(DMARDs)、雷公藤制剂等,种类限于1种,且在入组前已稳定剂量治疗至少4周,且入组后用药剂量保持不变;
7.入组前受试者使用非甾体抗炎药(NSAIDs)或其他镇痛药治疗RA,必须在入组前已稳定剂量治疗至少1周,且入组后用药剂量保持不变;
8.自愿参加试验并签署知情同意书。
|
Inclusion criteria
|
1.Meet the RA classification standard of American Rheumatology Society (ACR)/ European Union against Rheumatology (EULAR) in 2010;
2. TCM syndrome differentiation is wind (cold) dampness obstruction syndrome or liver and kidney deficiency syndrome;
3. Aged 18 to 75 years old;
4. DAS28(CRP) score > 3.2;
5. Before entering the group, the subjects should take glucocorticoid orally, and the dose should be stabilized to be equal to <=10mg/ day prednisone within at least 4 weeks before entering the group, and the dose should remain unchanged after entering the group;
6. Traditional anti-rheumatism drugs (DMARDs) and Tripterygium wilfordii preparations were used before entering the group, and the types were limited to one, and they had been treated with stable doses for at least 4 weeks before entering the group, and the dosage remained unchanged after entering the group;
7. Before entering the group, the subjects used NSAIDs or other analgesics to treat RA. They must have been treated at a stable dose for at least one week before entering the group, and the dosage remained unchanged after entering the group;
8. Volunteer to participate in the experiment and sign the informed consent form.
|
排除标准:
|
1.既往使用小分子靶向药物以及生物制剂治疗,停药<4周者;
2.既往使用祛风止痛胶囊,停药<4周者;
3.入组前4周内接受过关节内注射、肌注或静脉注射糖皮质激素包括促肾上腺激素治疗者;
4.入组前1周内接受过中药汤剂或中成药治疗者;
5.既往使用含有附子、川乌、草乌及相似成分的中药或中成药,停药<4周者;
6.妊娠、哺乳及近期有生育计划者;
7.合并心血管、脑、肝、肺、肾和造血系统等重要器官的严重疾病,急慢性感染性疾病,恶性肿瘤,精神性疾病患者;
8.血常规检查白细胞计数< 3.0×10^9/L,或血红蛋白< 90 g/L,或血小板计数<100.0×10^9/L的患者;
9.肝病活动期或肝功能异常,AST、ALT高于正常值上限1.2倍者;
10.肾功能异常,肌酐(Cr)高于正常值上限1.2倍者;
11.合并系统性红斑狼疮、硬皮病、干燥综合征等明确诊断的自身免疫性疾病者;
12.既往有肺间质性改变:
13.对甲氨蝶呤片、祛风止痛胶囊任何已知成分过敏者;
14.正在参加其它试验者或2个月内参加过其他药物临床试验者;
15.具有其他研究者认为不能加入此临床试验的情况。
|
Exclusion criteria:
|
1. Those who have been treated with small molecule targeted drugs and biological agents in the past and stopped taking drugs for less than 4 weeks;
2. Those who used Qufeng Zhitong Capsule before and stopped taking it for less than 4 weeks;
3. Those who have received intra-articular injection, intramuscular injection or intravenous injection of glucocorticoid including adrenocorticotropic hormone within 4 weeks before entering the group;
4. Those who have received traditional Chinese medicine decoction or Chinese patent medicine treatment within 1 week before entering the group;
5. Those who have used traditional Chinese medicines or proprietary Chinese medicines containing Aconitum carmichaeli, Aconitum carmichaeli, Aconitum kusnezoffii and similar ingredients in the past and stopped using them for less than 4 weeks;
6. Pregnancy, breastfeeding and recent family planning;
7. Patients with serious diseases such as cardiovascular, brain, liver, lung, kidney and hematopoietic system, acute and chronic infectious diseases, malignant tumors and mental diseases;
8. Patients with white blood cell count < 3.0x10^9/L, hemoglobin < 90 g/L, or platelet count < 100.0x10^9/L;
9. In the active stage of liver disease or abnormal liver function, AST and ALT are higher than the upper limit of normal value by 1.2 times;
10. Abnormal renal function, creatinine (Cr) is higher than the upper limit of normal value by 1.2 times;
11. Patients with autoimmune diseases such as systemic lupus erythematosus, scleroderma and Sjogren's syndrome;
12. There have been pulmonary interstitial changes in the past:
13. Allergic to any known ingredients of methotrexate tablets and Qufeng Zhitong capsules;
14. Those who are participating in other trials or who have participated in clinical trials of other drugs within 2 months;
15. There are cases where other researchers think that they cannot join this clinical trial.
|
研究实施时间:
Study execute time:
|
从From
2021-09-29
至To
2023-09-13
|
征募观察对象时间:
Recruiting time:
|
从From
2021-09-29
至To
2023-03-03
|